# Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer

> **NCT02218606** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 81 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Abiraterone acetate 1000 mg po daily
- **DRUG:** Cabazitaxel 25 mg/m2 IV
- **DRUG:** prednisone 5 mg po BID

## Key facts

- **NCT ID:** NCT02218606
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2023-10-13
- **Final completion:** 2023-10-13
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2024-12-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02218606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02218606, "Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02218606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*